| Bioactivity | GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP(33-41) TFA can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM[1]. | ||||||
| Invitro | GP(33-41) TFA sensitizes MC57 and T2-Db cells to lysis with ED50s of 0.9±0.6 and 2.5±0.7 nM[1]. The interaction between T cell receptors (TCR) and peptide-major histocompatibility complex (pMHC) antigens can lead to varying degrees of agonism (T cell activation), or antagonism. The P14 TCR recognises the lymphocytic choriomeningitis virus (LCMV)-derived peptide, GP(33-41) (KAVYNFATC), presents in the context of H-2D[2]. | ||||||
| Name | GP(33-41) TFA | ||||||
| Formula | C48H70F3N11O15S | ||||||
| Molar Mass | 1130.19 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
GP(33-41) TFA
CAS: F: C48H70F3N11O15S W: 1130.19
GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.